Clinical features and prognosis of 28 patients with ipsilateral double concurrent primary breast cancer

Objective: To investigate the clinicopathological features and prognosis of patients with ipsilateral double concurrent primary breast cancer. Methods: The clinical records and follow-up information of 28 patients with ipsilateral double concurrent primary breast cancer between January 2006 and January 2008 were reviewed retrospectively. Results: The two tumor lesions were detected by MRI with a high sensitivity of 90%. The coincidence rate of pathological type of the two tumor lesions was 64%. The two tumor lesions were both detected by immunochemistry in 10 cases, and the results showed that the expression status of estrogen receptor (ER) and progesterone receptor (PR) was consistent, but the expression status of Ki-67 and human epidermal growth factor receptor 2 (HER2) was inconsistent. The coincidence rate of molecular pathology of the two tumor lesions was 70%. Univariate prognostic analysis showed that the overall survival time of the patients with ipsilateral double concurrent primary breast cancer was significantly associated with tumor stage (P = 0.004) and ER status (P = 0.000). Tumor stage (P = 0.003), axillary lymph node status (P = 0.032) and ER status (P = 0.022) affected the disease-free survival time of the patients with ipsilateral double concurrent primary breast cancer. Multivariate prognostic analysis showed that tumor stage was an independent prognostic factor of ipsilateral double concurrent primary breast cancer. Conclusion: The coincidence rate of pathological type of two tumor lesions in ipsilateral double concurrent primary breast cancer is higher, and the tumor stage is an independent prognostic factor. DOI:10.3781/j.issn.1000-7431.2017.33.729